AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.

Revenue
+10.3%
EPS
+2,270.0%
Free cash flow
+9.97%
Total debt
+17.7%

Quarter to September 2026, against a year earlier

289.28 1.04 +0.36%
Market cap
$509.5B
P/E
49.7×
Fwd P/E
38.6×
Dividend yield
2.40%
F-score
8/9
Altman Z
2.31
Beneish M
−2.86
Dividend safety
44/100

AbbVie Inc. (ABBV) P/B ratio

Alert me on P/B ratio

AbbVie Inc. has no meaningful P/B ratio: its trailing twelve-month book value is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 253× (March 2025) — the current reading is the lowest in ten years.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 0.0× —
FY2024 93.4× 243.84%
FY2023 27.2× 63.37%
FY2022 16.6× 7.15%
FY2021 15.5× 13.84%
FY2020 13.6× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 30.8× 41.12%
FY2016 21.8× (10.52%)

Quarterly newest first

Period P/B ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
43 more quarters

Against its own ten years

Low 0.0× High 253×
Ten-year median 17.0×
Current reading's percentile 28

P/B ratio against peers

Company P/B ratio
ABBV AbbVie Inc. n/m
PFE Pfizer Inc. compare 1.9×
AZN AstraZeneca PLC compare 5.6×
JNJ Johnson & Johnson compare 8.1×
NVS Novartis AG compare 8.2×
MRK Merck & Co., Inc. compare 8.6×
GILD Gilead Sciences, Inc. compare 16.1×
AMGN Amgen Inc. compare 21.4×
LLY Eli Lilly and Company compare 30.3×
Drug Manufacturers General industry median 5.2×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on ABBV